Quintis officially opens new sandalwood oil distillation process at Albany

A-grade sandalwood oil now takes two days to distil instead of nine days, reducing the company’s carbon footprint per kilogram of oil produced.

Lacey Act Holds Importers Liable for Observing Supply Chain Regulations

New updates to the Lacey Act from October 1 will require a plant import declaration and will hold importers liable for observing regulations related to the import of 27 new tariff lines, including sandalwood essential oil. 

More antioxidant protection than powerhouse vitamin E

New cellular research recently published in the Cosmetics Journal has found that Indian sandalwood oil is a more potent antioxidant than the known lipophilic antioxidant vitamin E (alpha tocopherol).

Quintis Signs MOU with Leading TCM Manufacturer

On 10 March 2021, Quintis signed a memorandum of understanding with one of China's largest manufacturers of Traditional Medicines, Lanzhou Foci Pharmaceuticals.

2020 Harvest

During November, Quintis completed their 7th annual harvest which brings the total harvest amount to 500 hectares since the first harvest in 2013.

New Look Quintis

Recognising its unique product offering, the business understands that clients expect a ‘Uniquely Quintis’ experience, drawing upon their Australian roots, scientific rigor, ethical supply and progressive research. These elements have influenced a brand refresh, highlighting the aspects of their Indian (also known as Santalum album) and Australian sandalwood (also known as Santalum spicatum) products.

Perfumery in the New Normal

Quintis is proud to be one of Perfumer & Flavorist's major sponsors for this year's virtual education event, 'Perfumery in the New Normal'.

Quintis CEO Succession

The Board of Quintis is pleased to announce that Richard Henfrey has been appointed to succeed Julius Matthys as Chief Executive Officer of the Company. Mr Matthys will remain with the Company as a Non-Executive Director.

Recapitalisation of Quintis

A newly recapitalised Quintis (“Company”) has today emerged from receivership after receiving A$145 million in funding from its new owners, including funds and accounts under management by BlackRock Advisors, LLC and its affiliates.

Quintis Harvest Video

Our 2018 harvest season has now come to an end. Over the last few months our specialised harvest team successfully harvested approximately 13,600 Indian sandalwood trees on behalf of Quintis, an institutional investor and retail investors.

2018 Harvest Update

Phase 2 Clinical Study of Atopic Dermatitis (Eczema)

Santalis Pharmaceuticals Enrolls First U.S. Subject Into a Ph2 Clinical Study of Mild to Moderate Atopic Dermatitis (Eczema).

Australian Patent Covering the use of Sandalwood Oil to Treat Cancer

Santalis Pharmaceuticals announced the granting by the Australian Patent Office of Patent No. 2011223758 containing 16 claims covering the use of Sandalwood oil compositions to treat a variety of cancers including Leukemia and solid tumors such as bladder cancer and others.

Company Update | Cyclone Debbie

Quintis Queensland Indian Sandalwood plantations largely unaffected by Cyclone Debbie

Presentation to JP Morgan Healthcare Conference

Strong Indian Sandalwood Demand from China

In a global study of the Indian sandalwood industry, a leading management consultancy firm estimated that China will consume around 40% of all legal and authentic Indian sandalwood by 2025.

Notice of Filing & Hearing on Verified Petition under Chapter 15 of the United States bankruptcy code

Circular to MIS Growers - Federal Court Directions Hearing & Sale Process

TFS Name Change & Rebrand 2017

In March 2017 TFS will rebrand to Quintis.